-Down to Earth Prime minister's statement, agreeing to implement recommendations of India-US joint working group on intellectual property, would make medicines unaffordable for millions of needy, say health activists  Prime Minister Narendra Modi's stand on Intellectual Property Rights (IPR) became clear when he assured Barack Obama that his government is ready to follow the recommendations of the US-India joint working group. Modi made this statement on Monday while addressing the CEO Forum...

-The Telegraph New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India. The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines,...

-The Telegraph New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine. Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against...

-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...